Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PD-1/PD-L1 inhibitor

Merck turns to gamification in diabetes

Working with Ayogo on mobile app to improve adherence

- PMLiVE

FDA backs a brace of allergy immunotherapies

Merck & Co and Stallergenes win drug approvals in US

- PMLiVE

FDA backs new formulation of Noxafil

Merck wins US approval for delayed-release version of anti-infective

- PMLiVE

Merck stakes a claim to all-oral hepatitis C market

Positive data for interferon-free regimen

- PMLiVE

Merck’s vintafolide shows its worth in ovarian cancer

Phase II data shows improvement on current oncology treatments

- PMLiVE

Merck’s anti-PD1 drug promising in lung cancer

Positive results in phase Ib trial

- PMLiVE

R&D in the firing line as Merck & Co axes 8,500 jobs

Shake up to boost research productivity

- PMLiVE

FDA rejects Merck muscle relaxant drug once again

Regulator still has hypersensitivity concerns about Bridion

- PMLiVE

AZ licenses Merck ovarian cancer drug

Pays $50m upfront for MK-1775

- PMLiVE

Avanir to co-promote Merck’s diabetes drugs in the US

Will market Januvia and Janumet to care homes

- PMLiVE

Merck maintains lead in BACE inhibitors for Alzheimer’s

Positive results in phase Ib study in patients with Alzheimer’s disease

- PMLiVE

Setback for Merck & Co as FDA knocks back insomnia drug

US regulator asks for company to file for approval of a lower starting dose of suvorexant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links